ER stress and Parkinson's disease: Pathological inputs that converge into the secretory pathway

Brain Research

Volumn 1648, Issue , 2016, Pages 626-632

  Mercado, Gabriela ^a,b   Castillo, Valentina ^a,b   Soto, Paulina ^a,b   Sidhu, Anita ^c  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ER stress; Parkinson's disease; Pathogenesis; Secretory pathway; Unfolded protein response

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ACTIVATING TRANSCRIPTION FACTOR 6; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN IRE1; PROTEIN IRE1ALPHA; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

CELL SURVIVAL; CHRONIC STRESS; DISEASE COURSE; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM STRESS; GENE MUTATION; GENETICS; HOMEOSTASIS; HUMAN; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SECRETORY PATHWAY; UNFOLDED PROTEIN RESPONSE; ANIMAL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ENDOPLASMIC RETICULUM STRESS; HUMANS; PARKINSON DISEASE; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE;

EID: 84964579462     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2016.04.042     Document Type: Review

References (77)

1. Abeliovich, A., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000), 239–252.
2. Beilina, A., et al. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc. Natl. Acad. Sci. USA 111 (2014), 2626–2631.
3. Blanz, J., Saftig, P., Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance. J. Neurochem., 2016.
4. Boyce, M., et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 307 (2005), 935–939.
5. Burre, J., The synaptic function of alpha-Synuclein. J. Park. Dis. 5 (2015), 699–713.
6. Cabin, D.E., et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22 (2002), 8797–8807.
7. Chandra, S., et al. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc. Natl. Acad. Sci. USA 101 (2004), 14966–14971.
8. Chartier-Harlin, M.C., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364 (2004), 1167–1169.
9. Cho, H.J., et al. Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export. EMBO J. 33 (2014), 2314–2331.
10. Choi, W., et al. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett. 576 (2004), 363–368.
11. Chu, Y., et al. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 35 (2009), 385–398.
12. Chung, C.Y., et al. Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. Science 342 (2013), 983–987.
13. Colla, E., et al. Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo. J. Neurosci. 32 (2012), 3306–3320.
14. Conway, K.A., et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97 (2000), 571–576.
15. Cooper, A.A., et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313 (2006), 324–328.
16. Credle, J.J., et al. Alpha-Synuclein-mediated inhibition of ATF6 processing into COPII vesicles disrupts UPR signaling in Parkinson's disease. Neurobiol. Dis. 76 (2015), 112–125.
17. da Fonseca, T.L., Villar-Pique, A., Outeiro, T.F., The interplay between alpha-synuclein clearance and spreading. Biomolecules 5 (2015), 435–471.
18. Decressac, M., et al. TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. Proc. Natl. Acad. Sci. USA 110 (2013), E1817–E1826.
19. Decressac, M., Bjorklund, A., TFEB: pathogenic role and therapeutic target in Parkinson disease. Autophagy 9 (2013), 1244–1246.
20. Ding, X., Goldberg, M.S., Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PLoS One, 4, 2009, e5949.
21. Egawa, N., et al. The endoplasmic reticulum stress sensor, ATF6alpha, protects against neurotoxin-induced dopaminergic neuronal death. J. Biol. Chem. 286 (2011), 7947–7957.
22. Fouillet, A., et al. ER stress inhibits neuronal death by promoting autophagy. Autophagy 8 (2012), 915–926.
23. Gorbatyuk, M.S., et al. Glucose regulated protein 78 diminishes alpha-synuclein neurotoxicity in a rat model of Parkinson disease. Mol. Ther. 20 (2012), 1327–1337.
24. Halliday, M., Radford, H., Mallucci, G.R., Prions: generation and spread versus neurotoxicity. J. Biol. Chem. 289 (2014), 19862–19868.
25. Harding, H.P., et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 11 (2003), 619–633.
26. Harding, H.P., Zhang, Y., Ron, D., Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397 (1999), 271–274.
27. He, Q., et al. Treatment with trehalose prevents behavioral and neurochemical deficits produced in an AAV alpha-synuclein rat model of Parkinson's disease. Mol. Neurobiol., 2015.
28. Hetz, C., et al. The unfolded protein response: integrating stress signals through the stress sensor IRE1alpha. Physiol. Rev. 91 (2011), 1219–1243.
29. Hetz, C., Mollereau, B., Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat. Rev. Neurosci. 15 (2014), 233–249.
30. Hoozemans, J.J., et al. Activation of the unfolded protein response in Parkinson's disease. Biochem. Biophys. Res. Commun. 354 (2007), 707–711.
31. Imai, Y., Soda, M., Takahashi, R., Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275 (2000), 35661–35664.
32. Jousse, C., et al. Inhibition of a constitutive translation initiation factor 2alpha phosphatase, CReP, promotes survival of stressed cells. J. Cell Biol. 163 (2003), 767–775.
33. Kett, L.R., et al. Alpha-synuclein-independent histopathological and motor deficits in mice lacking the endolysosomal Parkinsonism protein Atp13a2. J. Neurosci. 35 (2015), 5724–5742.
34. Kitao, Y., et al. Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. Hum. Mol. Genet. 16 (2007), 50–60.
35. Klein, C., Westenberger, A., Genetics of Parkinson's disease. Cold Spring Harb. Perspect. Med., 2, 2012, a008888.
36. Ko, H.S., et al. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc. Natl. Acad. Sci. USA 106 (2009), 2897–2902.
37. Kosmaczewski, S.G., et al. The RtcB RNA ligase is an essential component of the metazoan unfolded protein response. EMBO Rep. 15 (2014), 1278–1285.
38. Kruger, R., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (1998), 106–108.
39. Kubota, K., et al. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J. Neurochem. 97 (2006), 1259–1268.
40. Kumari, U., Tan, E.K., LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J. 276 (2009), 6455–6463.
41. Lesage, S., Brice, A., Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18 (2009), R48–R59.
42. Lihui, S., et al. X-box-binding protein 1-modified neural stem cells for treatment of Parkinson's disease. Neural Regen. Res. 7 (2012), 736–740.
43. Lin, J.H., et al. IRE1 signaling affects cell fate during the unfolded protein response. Science 318 (2007), 944–949.
44. Maor, G., et al. Unfolded protein response in Gaucher disease: from human to Drosophila. Orphanet J. Rare Dis., 8, 2013, 140.
45. Martina, J.A., et al. TFEB and TFE3 are novel components of the integrated stress response. EMBO J., 2016.
46. Mazzulli, J.R., et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146 (2011), 37–52.
47. Mercado, G., Valdes, P., Hetz, C., An ERcentric view of Parkinson's disease. Trends Mol. Med. 19 (2013), 165–175.
48. Miura, E., et al. VPS35 dysfunction impairs lysosomal degradation of alpha-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease. Neurobiol. Dis. 71 (2014), 1–13.
49. Mollereau, B., et al. Adaptive preconditioning in neurological diseases – therapeutic insights from proteostatic perturbations. Brain Res., 2016.
50. Mollereau, B., Manie, S., Napoletano, F., Getting the better of ER stress. J. Cell Commun. Signal. 8 (2014), 311–321.
51. Mullin, S., Schapira, A., The genetics of Parkinson's disease. Br. Med. Bull. 114 (2015), 39–52.
52. Novoa, I., et al. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J. Cell Biol. 153 (2001), 1011–1022.
53. Omura, T., et al. Endoplasmic reticulum stress and Parkinson's disease: the role of HRD1 in averting apoptosis in neurodegenerative disease. Oxid. Med. Cell. Longev., 2013, 2013, 239854.
54. Park, J.S., et al. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Hum. Mutat. 32 (2011), 956–964.
55. Polymeropoulos, M.H., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997), 2045–2047.
56. Ray, A., et al. RTCB-1 mediates neuroprotection via XBP-1 mRNA splicing in the unfolded protein response pathway. J. Neurosci. 34 (2014), 16076–16085.
57. Ron, D., Walter, P., Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8 (2007), 519–529.
58. Sado, M., et al. Protective effect against Parkinson's disease-related insults through the activation of XBP1. Brain Res. 1257 (2009), 16–24.
59. Salganik, M., et al. The loss of glucose-regulated protein 78 (GRP78) during normal aging or from siRNA knockdown augments human alpha-synuclein (alpha-syn) toxicity to rat nigral neurons. Neurobiol. Aging 36 (2015), 2213–2223.
60. Samann, J., et al. Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J. Biol. Chem. 284 (2009), 16482–16491.
61. Shimura, H., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25 (2000), 302–305.
62. Shoulders, M.D., et al. Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep. 3 (2013), 1279–1292.
63. Silva, R.M., et al. CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J. Neurochem. 95 (2005), 974–986.
64. Spillantini, M.G., et al. Alpha-synuclein in Lewy bodies. Nature 388 (1997), 839–840.
65. Tabas, I., Ron, D., Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell Biol. 13 (2011), 184–190.
66. Tang, F.L., et al. VPS35 in dopamine neurons is required for endosome-to-Golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for alpha-synuclein degradation and prevention of pathogenesis of Parkinson's disease. J. Neurosci. 35 (2015), 10613–10628.
67. Tanji, K., et al. Trehalose intake induces chaperone molecules along with autophagy in a mouse model of Lewy body disease. Biochem. Biophys. Res. Commun. 465 (2015), 746–752.
68. Thayanidhi, N., et al. Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol. Biol. Cell 21 (2010), 1850–1863.
69. Urra, H., et al. When ER stress reaches a dead end. Biochim. Biophys. Acta 1833 (2013), 3507–3517.
70. Valdes, P., et al. Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1. Proc. Natl. Acad. Sci. USA 111 (2014), 6804–6809.
71. Vidal, R.L., Hetz, C., Crosstalk between the UPR and autophagy pathway contributes to handling cellular stress in neurodegenerative disease. Autophagy 8 (2012), 970–972.
72. Vilarino-Guell, C., et al. VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 89 (2011), 162–167.
73. Vitte, J., et al. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J. Neuropathol. Exp. Neurol. 69 (2010), 959–972.
74. Wang, T., Hay, J.C., Alpha-synuclein toxicity in the early secretory pathway: how it drives neurodegeneration in Parkinsons disease. Front. Neurosci., 9, 2015, 433.
75. Winslow, A.R., et al. Alpha-synuclein impairs macroautophagy: implications for Parkinson's disease. J. Cell Biol. 190 (2010), 1023–1037.
76. Yuan, Y., et al. Dysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegans. PLoS One, 6, 2011, e22354.
77. Zarranz, J.J., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 (2004), 164–173.